Edwards Lifesciences Corp (EW)

Industry Medical Devices

This stock can be held in an Investment ISA and an Investment Account

Sell

$79.01

Buy

$82.82

arrow-down$-0.21 (-0.26%)

Prices updated at 02 Apr 2026, 22:52 EDT

Prices minimum 15 mins delay

Prices in USD

Edwards Lifesciences Corp is a part of the healthcare sector. The company specializes in the treatment of structural heart disease. It manufactures heart valves and repair products used to replace or repair a patient's diseased or defective heart valve.

S&P 500

0.11%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Medical Devices

Chairman

Mr. Nicholas J. Valeriani

CEO

Mr. Bernard J. Zovighian

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

16,000

Head office

One Edwards Way

Irvine

United States

92614

+1 949 250-2500

investor_relations@edwards.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Donald E. Bobo,Jr Corporate Vice President, Strategy and Corporate Development	0.76m
Mr. Kieran T. Gallahue Independent Director	0.09m
Mr. Nicholas J. Valeriani Chairman of the Board	0.09m
Mr. Paul A. Laviolette Independent Director	0.11m
Mr. Steven R. Loranger Independent Director	0.09m
Ms. Leslie Stone Heisz Independent Director	0.12m
Mr. Scott B. Ullem Corporate Vice President and Chief Financial Officer	0.81m
Dr. David T. Feinberg, M.D.,PhD Independent Director	0.09m
Mr. Bernard J. Zovighian Director and Chief Executive Officer	1.19m
Mr. Daveen Chopra Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies	0.67m
Ms. Ramona A. Sequeira Independent Director	0.09m
Mr. Wayne T. Markowitz General Manager and Senior Vice President, Surgical Structural Heart	-
Ms. Annette Bruls Corporate Vice President, EMEACLA	0.73m
Mr. Daniel J. Lippis Corporate Vice President, Transcatheter Aortic Valve Replacemen	-
Ms. Leslie C. Davis Independent Director	0.09m
Mr. Andrew M. Dahl Principal Accounting Officer, Senior Vice President and Corporate Controller	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	70,079,435
BlackRock Inc	54,294,173
JPMorgan Chase & Co	50,117,052
State Street Corp	25,619,632
Vanguard	22,841,938

Director dealings

Date chevron-l-regular chevron-r-regular	Action
12 Dec 2025	-
12 Dec 2025	-
12 Dec 2025	-
12 Dec 2025	-
12 Dec 2025	-
12 Dec 2025	-
12 Dec 2025	-
11 Dec 2025	-
10 Dec 2025	-
10 Dec 2025	-
10 Dec 2025	-
09 Dec 2025	-
09 Dec 2025	-
09 Dec 2025	-
09 Dec 2025	-
08 Dec 2025	-
10 Dec 2025	-
09 Dec 2025	-
08 Dec 2025	-
08 Dec 2025	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.